GlassScriptPhysician profile
Allyson N Bailey
NPI 1386385425
$1,325.29
in general payments reported to CMS, 2019-2025
19 companies · $72.12 in 2025
The $72.12 reported for 2025 was less than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $686 · 2023: $524 · 2024: $43.68 · 2025: $72.12.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $639.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $639.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $244.97 | 2022-2025 | Zepbound, Mounjaro, Reyvow |
| Novo Nordisk INC | $187.12 | 2022-2023 | Ozempic, Rybelsus |
| Abbvie INC. | $186.94 | 2022-2024 | |
| Biohaven Pharmaceutical Holding Company LTD. | $181.07 | 2022 | |
| Glaxosmithkline, LLC. | $96.22 | 2023 | Trelegy Ellipta, Shingrix |
| Merck Sharp & Dohme LLC | $59.95 | 2022-2023 | Belsomra, Dificid |
| Astrazeneca Pharmaceuticals LP | $45.12 | 2022-2023 | Farxiga |
| Pfizer INC. | $43.27 | 2022-2023 | |
| Organon LLC | $42.15 | 2023 | Nexplanon |
| Idorsia Pharmaceuticals US INC | $36.15 | 2023 | Quviviq |
| Astellas Pharma US INC | $35.72 | 2023-2024 | Veozah |
| Amgen INC. | $27.41 | 2023 | Otezla, Repatha |
| Otsuka America Pharmaceutical, INC. | $22.99 | 2023 | Rexulti |
| Sanofi-Aventis U.S. LLC | $22.16 | 2022 | |
| Horizon Therapeutics Plc | $21.44 | 2023 | Krystexxa |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $21.13 | 2025 | |
| Biogen, INC. | $20.60 | 2025 | Zurzuvae |
| Exact Sciences Corporation | $16.52 | 2023 | Cologuard Collection Kit |
| Sumitomo Pharma America, INC. | $14.36 | 2025 | Gemtesa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Allyson Bailey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.